Atrial fibrillation (AF) is the commonest clinically significant arrhythmia and is associated with significant morbidity and mortality. Until recently, treatment options were very limited with the mainstay of treatment being the vitamin K antagonists (VKAs). The introduction of the direct-acting anticoagulants has changed the playing field by offering patients a choice, but at a price. The majority of South African (SA) patients are still deprived of this choice owing to financial constraints. We therefore set out to review oral anticoagulants and AF with a specific focus on our patient population. The focus of this review is to assist clinicians in their decision-making and prescribing practices.

Anticoagulants are categorised into two large subgroups: those affecting the rapidly flowing arterial systems and those affecting the more stasis-prone venous system. Thrombi in the venous system consist of a fibrin web encasing platelets and red blood cells. In contrast, thrombi in the arterial system consist largely of platelets with less fibrin. Drugs affecting coagulation are classified and subsequently designed to target specific sites of these thrombi. Drugs targeting arterial thrombi include the antiplatelet drugs (aspirin, clopidogrel, abciximab, epifibatide and tirofiban) and the fibrinolytics (streptokinase and alteplase). Drugs targeting venous or stasis-induced thrombi include the traditional anticoagulants (heparin, low-molecular-weight (LMW) heparins and fondaparinux), the VKAs (warfarin), and more recently the novel or direct-acting oral anticoagulants (DOACs) (dabigatran, rivaroxaban and apixaban).

In this review, we focus on the VKA warfarin and the DOACs dabigatran and rivaroxaban and their use in NVAF in the SA state sector. NVAF is common, and with the arrival of the DOACs, doctors in the public sector need to familiarise themselves with these drugs and their risks and benefits.

Methods
A systematic literature search was conducted of PubMed, Google Scholar and the TRIP database. The following Medical Subject Heading (MeSH) terms were used: ‘anticoagulants’, ‘vitamin K antagonists’, ‘warfarin’, ‘direct or novel acting anticoagulants’, ‘dabigatran’, ‘rivaroxaban’, ‘apixaban’, ‘pharmacology’, ‘monitoring’, ‘cost effectiveness’, ‘atrial fibrillation’, ‘risk stratification’, ‘guidelines’ and ‘South Africa’. Other databases consulted included the universities of Liverpool and California’s antiretroviral drug databases, Statistics South Africa, and the Joint United Nations Programme on HIV/AIDS (UNAIDS) regarding HIV statistics. Printed pharmacology textbooks were also consulted where electronic text was unclear.

Systematic reviews, randomised controlled trials, cohorts and case-control studies were included. Only studies published in English were included. Original research was included then compared with research or study types that best addressed the specific research questions. The research question for each topic in this review revolved around what the current gold standard is and how we can implement it in our setting. When available, SA literature was included. Case studies and case series were excluded, as were studies published in foreign languages and those not related to AF. Research published after 31 December 2017 was not included.

Results and discussion
To determine whether we can successfully introduce the DOACs in our setting, we reviewed a total of 113 references and included 40 publications that met our inclusion criteria. Of the 40 articles included, seven (see Table 4) directly addressed our research question: Will the use of DOACs be more cost-effective than warfarin for non-valvular AF (NVAF) in the public healthcare setting in SA? Fig. 1 represents a visual illustration of articles included and excluded.

Pharmacology and monitoring of warfarin and DOACs
Warfarin is a VKA and coumarin derivative acting on the cyclic interconversion of vitamin K in the liver. VKAs block γ-carboxylation of glutamate residues and inhibit vitamin K reductase. This process results in partially carboxylated and decarboxylated vitamin K-dependent clotting factors (II, VII, IX, X). These proteins lose their procoagulant effect because carboxylation is required to bring about a calcium-dependent conformational change in the coagulation proteins. Without this conformational change, coagulation proteins cannot bind to cofactors on phospholipid surfaces and coagulation fails. The anticoagulant proteins C and S are also inactivated by this process and can lead to a prothrombotic state, which is in most circumstances overcome by the effect of the VKAs. The intensity of the procoagulant effect is controlled by monitoring the international normalised ratio (INR) which represents the patient’s status on anticoagulation therapy. The INR is determined using a specific assay and correlates with the intensity of the anticoagulant effect.

A South African perspective
D J Laäs, MB ChB; M Naidoo, MB ChB, FCFP, MFamMed, MSc (Sports Medicine), PhD

Corresponding author: D Laäs (daniel.j.laas@gmail.com)
coagulation is monitored using the patient’s prothrombin time (PT) and is standardised by an international normalised ratio (INR) test.\(^9\) The INR is calculated as follows:\(^10\)

\[
\text{INR} = \left( \frac{\text{patient PT}}{\text{mean normal PT}} \right)
\]

Warfarin should be taken once daily at the same time every day. Two to three doses of warfarin are necessary for the INR to reach the therapeutic range. This delay in effect can be attributed to the different half-lives of the clotting factors. The vitamin K-dependent factors detected by the PT test undergo reduction at a rate proportional to their half-lives. Factor VII is reduced first, followed by factors X and II. The mean therapeutic INR is 2.5 (range 2.0 - 3.0), with the exception of a mitral prosthesis, which requires a mean INR of 3.0 (range 2.5 - 3.5).\(^11\)

INR monitoring should be commenced after two to three doses of treatment and differs for inpatients and outpatients. Inpatients require daily INRs until the therapeutic range has been achieved and maintained for 2 days. Outpatients can be monitored every 2 days until a stable INR has been achieved. Once the INR is stable, intervals between monitoring should not exceed 4 weeks. Current guidelines recommend monitoring intervals of up to 12 weeks in stable patients.\(^12\) Evidence suggests that more frequent monitoring results in more time in the therapeutic range (TTR).\(^13\) Patients at an increased risk of thromboembolic events require dual anticoagulation with LMW heparin or unfractionated heparin after being initiated on warfarin, because of warfarin’s effect on protein C and S and the 2 - 3-day delay in reaching the therapeutic range. Dual anticoagulation can be stopped once the INR has been within the desired therapeutic range for 2 days or when two INR measurements taken 24 hours apart are within the therapeutic range. Patients with stable conditions (including chronic AF) can be started on VKAs on an outpatient basis without additional anticoagulant cover at a loading dose of 10 mg for healthy individuals.\(^14\)

Warfarin is also known to interact with numerous drugs and with foods such as green leafy vegetables. These vegetables have naturally high vitamin K levels and interact with VKAs.\(^15\) Various drugs affect warfarin’s metabolism, either potentiating or reducing its effectiveness. Warfarin consists of an S- and an R-enantiomer. The S-enantiomer is the more potent of the two and drugs such as clotrimazole and metronidazole, which inhibit its metabolism, potentiate warfarin’s effects.\(^16\) Drugs affecting the R-enantiomer, such as the proton-pump inhibitor omeprazole and the \(H_2\) antagonist cimetidine, have a lesser effect on PT and INR. Long-term paracetamol and alcohol use have been found to alter the clearance of warfarin, although short-term alcohol use was found to have a negligible effect on PT. Chronic alcohol use increases the clearance of warfarin and lowers the INR.\(^17\) Chronic paracetamol use increases the anticoagulant effect of warfarin through a toxic metabolite that inhibits vitamin K oxide reductase.\(^18\) Rifampicin, barbiturates, carbamazepine, grisofulvin, aminoglutethimide, nafcillin and dicloxacillin are powerful inducers of warfarin metabolism and decrease its effectiveness.\(^19\)

Antiretroviral medication influences warfarin concentration to various degrees, but high-quality, peer-reviewed evidence of the exact mechanisms is lacking. The protease inhibitors appear to decrease the effects of warfarin, with ritonavir decreasing R-enantiomer levels and lopinavir inducing CYP2C9.\(^14\) Nevirapine and efavirenz alter warfarin levels to various degrees through complex mechanisms, and frequent drug monitoring is required.\(^20\) Currently there is little evidence to suggest that the common nucleoside/nucleotide analogues have a clinically significant effect on a patient’s INR.\(^15,16\)

The DOACs, which include dabigatran, rivaroxaban and apixaban, were designed because of the limitations associated with warfarin use. Dabigatran or the prodrug dabigatran etexilate is a reversible direct thrombin inhibitor and prevents the conversion of fibrinogen to fibrin.\(^21\) Because this drug causes reversible inhibition of thrombin, it leaves a small amount of free active thrombin to assist with haemostasis.\(^22\) Routine drug monitoring is not recommended by the manufacturer or by the American College of Chest Physicians, as dabigatran has a relatively predictable pharmacological profile. Ecarin clotting time can be used to monitor the effect of this drug, but neither the PT nor the activated partial thromboplastin time (aPTT) can be used, as there is no linear correlation between dabigatran concentration and aPTT levels.\(^16\) As dabigatran is renally excreted, some authors do recommend drug monitoring in patients with renal impairment.\(^23\)

Rivaroxaban is a direct and reversible inhibitor of factor Xa that inhibits both free and clot-bound factor Xa, resulting in its anticoagulant effect. As with dabigatran, no routine drug monitoring is required, although unlike dabigatran, rivaroxaban has a predictable effect on the PT and to a lesser extent the aPTT.\(^24\) Apixaban, like rivaroxaban, is a factor Xa inhibitor.\(^20\)
Managing a patient who requires anticoagulation

Anticoagulation is complex, as there are several indications, agents and dosing regimens to choose from. In the SA public healthcare sector these complexities are exacerbated by our diverse patient populations, some of whom have multiple comorbidities, and limited access to the various anticoagulants available. Numerous international guidelines are available for outpatient anticoagulation and prevention of thromboembolic events. Guidelines that are widely used include the 2012 American College of Chest Physicians (ACCP) (9th edition) and the 2011 British Journal of Haematology (BJH) guidelines.[22]

The 2011 BJH guidelines on oral anticoagulation with warfarin are widely used in SA and are often referenced by the National Health Laboratory Service. Differences between these two guidelines are set out in Table 1. Most clinicians refer to the ACCP guidelines when making a decision on managing patients who require anticoagulation, as these guidelines are more comprehensive than the BJH guidelines.

There are several noteworthy updates to the 9th edition of the ACCP guidelines, and one that will have a major effect on patient load and expenses is the frequency of INR monitoring. Traditionally patients are seen at 4-week intervals to check whether their INRs are in the therapeutic range, but the update recommends that this may be lengthened to 12 weeks. Patients become eligible for this prolonged follow-up if they have consistently stable INRs without requiring dose adjustment.[23] The implementation of such a recommendation has the potential to significantly decrease cost and patient load on the healthcare system. Our own research has shown that a major driver of cost is number of clinic visits in managing patients with monthly INRs, and a major driver of patient dissatisfaction is number of consultations and venepunctures.[23] The ACCP guidelines recommend using dabigatran 150 mg twice daily instead of warfarin for treating NVAF for patients at intermediate and high risk for stroke (recommendation 2.1.11, grade 2B recommendation and level of evidence).[21]

Unfortunately, there are no recent anticoagulation guidelines specific to SA. Implementing North American and European guidelines is difficult in the SA setting owing to the high prevalence of HIV, as these new drugs are poorly studied in this subgroup of patients. In 2016 SA had an estimated 7.1 million people living with HIV, 19% of the global HIV population, of whom 56% had access to antiretroviral treatment.[24] This population of patients are at risk of developing deep-vein thrombosis.[25]

Risk stratification and initiation of treatment

Risk stratification is particularly useful in deciding when to initiate treatment in patients with NVAF. Several scoring systems have been devised to better manage patients with NVAF. The two most popular are the CHA2DS2-VASc and CHADS2 scores, CHA2DS2-VASc being the updated scoring system of the original CHADS2 score.[25]

Table 2 highlights the different components of the CHA2DS2-VASc score. CHA2DS2-VASc is an acronym that helps to determine a patient’s annual stroke risk.[24] The maximum score is 9 points.

### Table 1. Differences between guidelines on anticoagulation with warfarin

<table>
<thead>
<tr>
<th>Indications</th>
<th>2011 BJH guidelines[22]</th>
<th>2012 ACCP guidelines (9th edition)[22]</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTE, APS, AF, cardiovascular, valvular heart disease and prosthetic valves, peripheral vascular disease and myocardial infarction and cardiomyopathy</td>
<td>DVT/PE, AF or atrial flutter, CAD, valvular and rheumatic heart disease, and prevention of VTE for orthopaedic surgery</td>
<td></td>
</tr>
<tr>
<td>Initiation of treatment</td>
<td>No evidence to suggest that a 10 mg loading dose is superior to a 5 mg loading dose</td>
<td>In healthy outpatients with VTE, initiating treatment at a dose of 10 mg daily for 2 days followed by dosing based on INR measurements, rather than starting with the estimated maintenance dose, is recommended. This decreases the number of doses of LMWH and achieves a therapeutic INR sooner.</td>
</tr>
<tr>
<td>Management of bleeding and of an elevated INR without bleeding</td>
<td>Major bleeding: • Administer 25 - 50 U/kg of four-factor PC AND 5 mg IV vitamin K Non-major bleed: • Administer 1 - 3 mg of IV vitamin K Non-bleeding patient: • INR 5.0 - 7.9: withhold 1 - 2 doses of warfarin, reduce maintenance dose and investigate cause of elevated INR • INR &gt;8.0: 1 - 5 mg of oral vitamin K</td>
<td>VKA-associated major bleed: • Rapid reversal with four-factor PC rather than with plasma, and vitamin K 5 - 10 mg administered by slow IV injection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congestive heart failure (C)</td>
<td>1</td>
</tr>
<tr>
<td>Hypertension (B): Blood pressure consistently &gt;140/90 mmHg (or treated hypertension on medication)</td>
<td>1</td>
</tr>
<tr>
<td>Age ≥75 years (A)</td>
<td>2</td>
</tr>
<tr>
<td>Diabetes mellitus (D)</td>
<td>1</td>
</tr>
<tr>
<td>Prior stroke or TIA or thromboembolism (S)</td>
<td>2</td>
</tr>
<tr>
<td>Vascular disease (V)</td>
<td>1</td>
</tr>
<tr>
<td>Age 65 - 74 years (A)</td>
<td>1</td>
</tr>
<tr>
<td>Sex category (female sex) (Sc)</td>
<td>1</td>
</tr>
</tbody>
</table>

TIA = transient ischaemic attack.

---

**Notes:**

- BH = British Journal of Haematology; ACCP = American College of Chest Physicians; VTE = venous thromboembolism; APS = antiphospholipid syndrome; AF = atrial fibrillation; DVT = deep-vein thrombosis; PE = pulmonary embolus; CAD = coronary artery disease; INR = international normalised ratio; LMWH = low-molecular-weight heparin; PC = prothrombin complex; IV = intravenous; VKA = vitamin K antagonist.
These models incorporate the major risk factors for ischaemic stroke and give an unadjusted ischaemic stroke rate as a percentage per year. A score of 0 requires no anticoagulation, although there are exceptions to this rule. A score of ≥2 (high risk for thromboembolism) is a strong indication for anticoagulation with either DOACs or VKAs, while there is some controversy regarding a score of 1 (intermediate risk for thromboembolism). Some clinicians choose to anticoagulate patients with a score of 1, while others choose to withhold therapy.

Patients who qualify for and are initiated on oral anticoagulation have an increased risk of bleeding. This increased risk of bleeding is usually offset by the benefit obtained from thromboembolism risk reduction, although there are certain instances where this is not the case. For this reason, the HAS-BLED scoring system (Table 3) was developed. The HAS-BLED score is a simple and practical score that is used to determine a patient’s annual bleeding risk. Oral anticoagulation bleeding risk outweighs the benefits of treatment if the HAS-BLED score exceeds the CHADS2 score in patients with a CHADS2 score >2. In patients with a CHADS2 score of 1, a HAS-BLED score >2 should prompt the doctor not to consider oral anticoagulation.

The maximum score is also 9 points. Fig. 2 illustrates a practical approach to treating patients with NVAF by combining the HAS-BLED and CHA2DS2-VASc scores.

**Valvular AF**

Rheumatic and mechanical prosthetic heart valves, with or without comorbid AF, require anticoagulation with VKAs. Dabigatran is contraindicated in patients with prosthetic heart valves, and rivaroxaban and apixaban are unstudied in this population group. The RE-ALIGN trial was stopped during phase two owing to an increase in thromboembolic events and bleeding in the dabigatran subgroup. Investigators have attempted to explain this complication by suggesting that there was an incorrect selection of dabigatran trough levels and a possible decrease in dabigatran’s effectiveness during a postoperative hypercoagulable state. A notable exception to this rule is the bioprosthetic valves, which carry a relatively low risk of thrombosis, but there is limited evidence to suggest that some DOACs may be a suitable alternative to conventional anticoagulation in these patients.

**Effectiveness of the available oral anticoagulants**

The ROCKET-AF, ARISTOTLE and RE-LY studies have found the DOACs to be non-inferior to warfarin, and in some cases superior. Dabigatran 150 mg twice daily was associated with a stroke rate of 1.11% per year for patients with NVAF compared with a dose-adjusted warfarin (p<0.001). Rates of major bleeding for dabigatran 150 mg and dose-adjusted warfarin appear to be similar, but there is a significantly decreased risk of life-threatening intracranial bleeds with dabigatran 110 mg (0.12%; p<0.001) and 150 mg (0.10%; p<0.001) compared with warfarin (0.38%).

Rivaroxaban showed similar results, with a significant reduction in fatal bleeds in comparison with warfarin (0.2% v. 0.5%; p=0.003). An important finding of the ROCKET-AF trial was the TTR for patients on warfarin, which was only 55%. Some authors have mentioned that this is a confounding factor in ROCKET-AF. There is no internationally acceptable TTR for clinical trials, although Connolly et al. showed that there is little benefit of oral anticoagulation over conventional antplatelet therapy if the TTR is <58 - 65%. A similar comment can be made when evaluating the ARISTOTLE trial in which 18 201 patients were enrolled. Apixaban was found to be more effective than warfarin in preventing stroke and systemic embolism with lower rates of bleeding. Patients on warfarin had a mean TTR of 62% and a median TTR of 66%. Possible explanations for warfarin’s TTR in this study include non-compliance, drug-drug interaction, drug-food interactions and patient comorbidities.

The DOACs require less monitoring and have fewer drug interactions than the VKAs, but they do have distinct disadvantages.
A major concern for healthcare providers is the absence of a readily available antitode or reversal agent. A reversal agent for dabigatran is available in the form of idarucizumab (Praxbind), a monoclonal antibody, but there are none for any of the factor Xa inhibitors. Currently Praxbind is available in SA as a section 21 drug at a cost of ZAR32 000 including value-added tax. Section 21 of the Medicines and Related Substances Control Act (No. 101 of 1965) authorises the sale of unregistered orthodox medicine, complementary medicine, veterinary medicine or devices for certain purposes. Management of major bleeds revolves around haemodialysis, administering an antifibrinolytic agent and prothrombotic clotting factors. High-quality evidence is lacking for these interventions.

Warfarin has three distinct advantages over these drugs: no dose adjustment is required when treating patients with renal failure, therapeutic monitoring is readily accessible, and the antitode is readily available.

Cost and cost-effectiveness

In a resource-constrained setting such as SA, costs need to be balanced against efficacy and quality of life. This is determined by the cost-effectiveness ratio (CER) per quality-adjusted life year (QALY). A CER of <50 000 USD is considered desirable and a CER >100 000 USD is considered less desirable. In the UK, a CER of <30 000 GBP is desirable. Published cost-effectiveness analyses have been conducted using mostly Markov decision models and estimated costs. Harrington et al. concluded that dabigatran, rivaroxaban and apixaban are all cost-effective alternatives to warfarin, with none of these drugs having a CER >100 000 USD. Freeman et al. concluded that high-dose dabigatran had a CER of USD45 372 per QALY, and Shah and Gage calculated the CER at USD86 000 per QALY.

In 2013, Coyle et al. conducted one of the first cost-effectiveness analyses of the three new anticoagulants apixaban, dabigatran and rivaroxaban. They came to a similar conclusion as previous authors, with high-dose dabigatran the dominant treatment option and a cost-effective alternative to warfarin at a CER of USD20 797. Apixaban was considered as a cost-effective alternative at a CER of USD24 312. Low-dose dabigatran and rivaroxaban were found to have an unfavourable cost-effectiveness analysis, with a CER of >50 000 USD. Canestaro et al. published a cost-effectiveness analysis that concluded that the only cost-effective treatment option was apixaban. In their analyses the CERs of apixaban, rivaroxaban and dabigatran were USD93 063, USD111 465 and USD140 557, respectively. Their results were in contrast to previous published studies and concluded that both dabigatran and rivaroxaban, although contributing significantly to QALYs, were not cost-effective treatment options. These results are largely due to the authors assigning a price of USD4 per month for warfarin, in contrast to other authors who assigned it a cost of USD30 per month. These studies affirm that there is still much uncertainty when determining whether these drugs are cost-effective alternatives to warfarin. Reasons for this uncertainty include authors assigning different costs under different economic climates. Table 4 compares the cost-effectiveness studies used in this review.

As a by-product of the cost-effectiveness analyses, these studies did emphasise one important point: that the DOACs provide patients with a superior quality of life compared with warfarin. QALYs gained varied between different studies, but it appears that the DOACs were consistently superior to warfarin regardless of individual CHADS2 scores. In their base-case analysis, Harrington et al. calculated that dabigatran 150 mg added 8.41 QALYs and apixaban 5 mg 8.47 QALYs compared with 7.97 QALYs for dose-adjusted warfarin. This is in keeping with the results of Freeman et al. who concluded that high-dose dabigatran contributed an additional 0.56 QALYs in comparison with warfarin. Rivaroxaban 20 mg was found to contribute 0.22 QALYs when compared with dose-adjusted warfarin. These findings are broadly in keeping with the results of Coyle et al. who showed that dabigatran 150 mg was the dominant treatment option in terms of QALYs and CER, followed closely by apixaban, rivaroxaban and dabigatran 110 mg.

Cost implications for SA

Little research has been conducted on the cost-effectiveness of the DOACs in an SA setting. Bergh et al. conducted a cost-effectiveness analysis of dabigatran as first-line therapy for stroke prevention in AF in the SA private sector. They estimated an incremental CER of ZAR93 290 per QALY when comparing dose-adjusted warfarin with dabigatran. They concluded that dabigatran is a cost-effective alternative to warfarin in the SA private sector. Their economic appraisal is useful, but it is difficult to interpret in the context of the SA public sector. No threshold amount exists for willingness to pay per QALY in SA. If one were to convert the current US threshold of USD100 000 to ZAR, at the exchange rate at the time of writing (ZAR13.50 per USD, 15 December 2017), South Africans would be expected to pay ZAR1 350 000 per QALY gained. In a country with an unemployment rate of 27.7%, ZAR93 290 per QALY would be unaffordable for a large portion of the population. Symons appears to have come to a similar conclusion in his review article, stating that for the time being the DOACs are too expensive to introduce in the vast majority of SA population groups. These findings are in keeping with our own cost-effectiveness analysis. Warfarin was found to be significantly more cost-effective than the DOACs, even when a wide range of warfarin-related expenses was included.

Study limitations

This review is not intended to be a comprehensive account of all available literature on anticoagulants, but rather to highlight the difficulties and limitations associated with prescribing anticoagulants in SA and to provide some clarity to the clinician.

The major limitation of this review is the paucity of SA literature. The context in which care is rendered in developed countries differs from that in SA, and implementing their recommendations in our public healthcare setting would inevitably prove challenging. The international literature and research on this topic are constantly evolving, so the potential for research included in this review to become outdated is a further limiting factor.

Conclusions

Anticoagulation is an ever-evolving area with constant updates on new drugs and management protocols. The challenge for doctors in SA is the lack of substantive data to support the use of the DOACs for the majority of patients who access care in the public sector. For the foreseeable future, warfarin will remain the mainstay of oral anticoagulation. It is inexpensive and readily available, and doctors are comfortable prescribing it. However, doctors should familiarise themselves with the DOACs, as they have distinct advantages over warfarin and their availability will increase as cheaper generic alternatives become available.

Acknowledgements. DJL thanks his wife Dr R Laas for assisting with editing.

Author contributions. DJL was the principal investigator and MN the research supervisor.

Funding. A research grant was obtained from the South African Medical Association. The authors state that this grant had no influence on the results and conclusions of this article.

Conflicts of interest. None.
Table 4. Comparison of cost-effectiveness studies

<table>
<thead>
<tr>
<th>Authors, year, study name, reference no.</th>
<th>Study population</th>
<th>Main finding</th>
<th>Funding</th>
<th>Conflict of interest</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harrington AR, Armstrong EP, Nolan PE, Malone DC. 2013. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation[41]</td>
<td>A hypothetical cohort of 70-year-old patients with NVAF at an increased risk of stroke</td>
<td>The NOACs evaluated in this study were more cost-effective treatment options than warfarin for stroke prevention in patients with NVAF</td>
<td>BFG was supported by the American Heart Association. SVH was supported by the Knowlton Foundation and a fellowship at Washington University in St Louis, USA</td>
<td>None disclosed</td>
</tr>
<tr>
<td>Shah SV, Gage BE. 2011. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation[42]</td>
<td>A hypothetical cohort of 70-year-old patients with AF with a moderate risk of stroke and no contraindication to anticoagulant therapy</td>
<td>Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of haemorrhage or high risk of stroke unless INR control with warfarin was excellent. Warfarin was cost-effective in moderate-risk AF populations unless INR control was poor.</td>
<td>American Heart Association and Veterans Affairs Health Services Research and Development Service</td>
<td>None disclosed</td>
</tr>
<tr>
<td>Freeman JV, Zhu RP, Owens DK, et al. 2011. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation[42]</td>
<td>The RE-LY trial and other published studies of anticoagulation</td>
<td>In patients aged ≥65 years with NVAF at increased risk for stroke (CHADS, score 1 or equivalent), dabigatran may be a cost-effective alternative to warfarin depending on pricing in the USA.</td>
<td>A grant from the Canadian Institutes of Health Research Drug Safety and Effectiveness Network</td>
<td>None mentioned</td>
</tr>
<tr>
<td>Coyle D, Coyle K, Cameron C, et al. 2013. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation[42]</td>
<td>A typical patient profile from the RE-LY study was adopted: average age 72 years with no previous stroke or myocardial infarction</td>
<td>Results were highly sensitive to patient characteristics. Rivaroxaban and dabigatran 110 mg were unlikely to be cost-effective. For different characteristics, apixaban or dabigatran 150 mg were optimal.</td>
<td>A grant from CVS Caremark to Brigham and Women's Hospital, USA</td>
<td>Publication of the study results was not contingent on the sponsor’s approval or censorship of the manuscript</td>
</tr>
<tr>
<td>Canestano WJ, Patrick AR, Avorn J, et al. 2013. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation[42]</td>
<td>A theoretical cohort of 70-year-old patients with an average CHADS, score of 2</td>
<td>Apixaban seems to be the optimal anticoagulation strategy. Warfarin seems to be the optimal choice in an equal number of simulations. As a result, although all the NOACs produce greater quality-adjusted life expectancy than warfarin, they may not represent good value for money.</td>
<td>CIC has received research funding from Janssen Pharmaceuticals</td>
<td>None disclosed</td>
</tr>
<tr>
<td>Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. 2013. Cost-effectiveness of dabigatran compared to warfarin for stroke prevention in atrial fibrillation[42]</td>
<td>A cohort of patients aged 65 years with AF at high risk of stroke (CHADS, score 3) and no contraindications to anticoagulation</td>
<td>Rivaroxaban may be a cost-effective alternative to warfarin in patients with AF regardless of baseline ischaemic stroke risk.</td>
<td>The study was funded by Boehringer Ingelheim SA</td>
<td>CIC and JK were members of the Janssen Pharmaceuticals speaker’s bureau</td>
</tr>
</tbody>
</table>

NVAF = non-valvular atrial fibrillation; AF = atrial fibrillation; RE-LY = Randomized Evaluation of Long-Term Anticoagulation Therapy; SA = South Africa/n; NOACs = novel oral anticoagulants; INR = international normalised ratio.


Accepted 17 May 2018.